Healthcare Providers and Services
Company Overview of Onco360
Onco360 provides oncology pharmaceuticals and care management services for physicians, patients, payers, and pharmaceutical manufacturers in the United States. It offers OncoSource, a total sourcing solution that offers drug pedigree, and no clinical fragmentation (oral, injected, infused, and limited distribution products); OncoDose, a fulfillment model that delivers treatment day/dose dispensing, as well as stat and emergency dose capabilities; OncoMTM, a medication treatment management program that helps improve safety, reduce adverse events, and drive compliance. The company also provides OncoPaths, which facilitates concordance with pathways subject to NCCN, ASCO, or payer evidence-base...
410 Park Avenue
New York, NY 10022
Founded in 2003
Key Executives for Onco360
Chief Executive Officer and President
Vice Chairman and Chief Strategy Officer
Scientific Advisory Council Partner
Compensation as of Fiscal Year 2014.
Onco360 Key Developments
Bayer Selects Onco360 as Limited Distribution Pharmacy Provider
Jan 5 15
Onco360 announced that it has been selected by Bayer AG as a limited distribution pharmacy network participant for two of its leading oncology medications, Nexavar (sorafenib) and Stivarga (regorafenib). With the addition of these two medications, Onco360's oncology medication portfolio now comprises nearly 40 limited distribution products. Both of the new additions to Onco360's portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment and are immediately available for order through Onco360.
Pfizer Selects Onco360 as Limited Distribution Pharmacy Provider
Dec 1 14
Onco360 announced that it has been selected as a limited distribution pharmacy network participant by Pfizer Inc. and can immediately begin dispensing Bosulif(R) (bosutinib), Inlyta(R) (axitinib), Sutent(R) (sunitinib), and Xalkori(R) (crizotinib). With the addition of these four medications. Each of the new additions to Onco360's portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment: Bosulif, a treatment for chronic, accelerated, or blast phase Philadelphia chromosome positive chronic myelogenous leukemia in adult patients with resistance or intolerance to prior therapy; Inlyta, a treatment for advanced renal cell carcinoma in patients after failure of one prior systemic therapy; Sutent, a treatment for three forms of cancer, including advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; and Xalkori, a treatment for patients with metastatic ALK-positive non-small cell lung cancer.
Onco360 Appoints Paul Jardina as President and Chief Executive Officer
Oct 27 14
Onco360 announced that Paul Jardina has been named President and Chief Executive Officer. Mr. Jardina has more than 20 years of healthcare industry experience as an executive in oncology and physician services. Most recently he served as President and CEO of U.S. Physiatry, a physician services company focused on physical medicine and rehabilitation in the post-acute continuum. Mr. Jardina has served in various leadership positions for U.S. Oncology (now McKesson Specialty Health), leading key business lines, including oncology specialty pharmacy, drug distribution, and radiation and imaging. In his role at U.S. Oncology, Mr. Jardina was instrumental in the development and growth of the company's pharmaceutical service lines and its transition to an open market provider of oncology pharmaceutical services.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|